6505--Bevacizumab Injection
ID: 36E79725R0019Type: Solicitation
Overview

Buyer

VETERANS AFFAIRS, DEPARTMENT OFVETERANS AFFAIRS, DEPARTMENT OFNAC PHARMACEUTICALS (36E797)HINES, IL, 60141, USA

NAICS

Pharmaceutical Preparation Manufacturing (325412)

PSC

DRUGS AND BIOLOGICALS (6505)

Original Source

https://sam.gov/opp/db8bdca840154d55bfed9f0551fa140c/view
Timeline
    Description

    The Department of Veterans Affairs is soliciting proposals for the procurement of Bevacizumab injections, a critical pharmaceutical product used in various healthcare settings for veterans. Vendors are required to meet specific criteria, including providing unique National Drug Codes (NDC) and adhering to the Drug Supply Chain Security Act regulations, as the contract aims to ensure a reliable supply of this medication across government health care facilities. The selected contractor will be responsible for multiple line items of different Bevacizumab formulations, maintaining compliance with FDA manufacturing practices, and submitting quarterly sales reports, including cost recovery fees. Interested vendors should contact Contract Specialist Matthew S. Poulin at Matthew.Poulin@va.gov for further details, with submissions due by the specified deadlines outlined in the solicitation document.

    Point(s) of Contact
    Matthew S PoulinContract Specialist
    Matthew.Poulin@va.gov
    Files
    Title
    Posted
    36E79725R0019_1.docx
    The presolicitation notice issued by the Department of Veterans Affairs pertains to the procurement of Bevacizumab Injection (Product Service Code 6505, NAICS Code 325412). The notice includes essential details such as the solicitation number (36E79725R0019), response deadline scheduled for March 4, 2025, at 2:30 PM Central Time, and archival information specifying that documents will be archived 99 days post-response. The contracting office is located at Building 37, Hines, IL 60141, with the designated point of contact being Contract Specialist Matthew Poulin, available at 708-786-5186 or via email at Matthew.Poulin@va.gov. The notice highlights the procedural aspects of the procurement process and lays the groundwork for bidding on this essential pharmaceutical product, which serves the healthcare needs of veterans. Overall, it reflects the government's commitment to ensuring the availability of critical medications through structured procurement practices.
    36E79725R0019.docx
    The document outlines a Requisition by the Department of Veterans Affairs for pharmaceutical products, specifically Bevacizumab injections, through a competitive solicitation process (SF-1449). It specifies the requirements for vendors to participate, including providing unique National Drug Codes (NDC) and compliance with Drug Supply Chain Security Act regulations. The contract is structured to award a single vendor for multiple line items encompassing different formulations of Bevacizumab, involving an obligatory price structure and cost recovery fee. Key details include the submission deadlines, evaluation criteria, and provisions for maintaining supplier and compliance standards throughout the contract duration. The procurement aims to ensure consistent product availability for various government health care facilities while adhering to federal guidelines for pharmaceuticals. The contractors must have FDA-approved manufacturing practices and provide quarterly sales reports, including the collected cost recovery fees. The document emphasizes the importance of proper supply chain management and compliance with the regulatory frameworks essential for government contracts, reflecting the government's commitment to securing reliable pharmaceutical resources for veterans' healthcare needs.
    Lifecycle
    Title
    Type
    6505--Bevacizumab Injection
    Currently viewing
    Solicitation
    6505--Bevacizumab Injection
    Presolicitation
    Similar Opportunities
    6505--Rituximab and Biosimilars
    Buyer not available
    The Department of Veterans Affairs is soliciting proposals for the procurement of Rituximab 10mg/ml and its biosimilars, aimed at establishing a reliable pharmaceutical supply source for government healthcare facilities. Bidders are required to provide unique National Drug Code (NDC) numbers for their products and include a 0.5% Cost Recovery Fee in their pricing, with the contract covering a base year and four optional subsequent years. This procurement is critical for ensuring consistent product availability and pricing based on estimated annual usage, while adhering to FDA regulations and the Drug Supply Chain Security Act (DSCSA) for safety and traceability. Interested suppliers must submit their proposals by March 11, 2025, at 2:30 PM CT, and can contact Contract Specialist Deborah S Fassl at Deborah.Fassl@va.gov for further information.
    6505--Insulin (VA-25-00026482)
    Buyer not available
    The Department of Veterans Affairs is soliciting proposals for the procurement of insulin and related pharmaceutical products under the solicitation titled "6505--Insulin (VA-25-00026482)." This procurement aims to establish a reliable supply source for the Department of Veterans Affairs and the Department of Defense, requiring offerors to submit competitive pricing for a base year plus four option years, including a 0.5% Cost Recovery Fee. Compliance with the Drug Supply Chain Security Act (DSCSA), adherence to current good manufacturing practices (cGMP), and provision of unique National Drug Codes (NDC) for the offered products are critical requirements. Interested parties should direct inquiries to Contract Specialist Billy Fong at Billy.Fong@va.gov, with proposals due by the specified deadline outlined in the solicitation document.
    6505--Fluticasone Propionate 50 MCG/Spray Soln, Nasal, 16GM
    Buyer not available
    The Department of Veterans Affairs is soliciting bids for the supply of Fluticasone Propionate nasal spray, a pharmaceutical product essential for various government healthcare facilities. Offerors are required to submit pricing for a base year and four option years, including a 0.5% Cost Recovery Fee, while ensuring compliance with federal standards and providing a unique National Drug Code (NDC) for each product. This procurement aims to secure reliable pharmaceutical sources to support healthcare services for veterans and other governmental health programs, adhering to strict FDA guidelines and good manufacturing practices. Interested contractors should contact Contract Specialist Michael J Olszewski at Michael.Olszewski@va.gov for further details on submission procedures and compliance requirements.
    6505--Diclofenac Sodium (NA) 1% Gel
    Buyer not available
    The Department of Veterans Affairs (VA) is soliciting proposals for the supply of Diclofenac Sodium (NA) 1% Gel, intended for use in its pharmaceutical programs as well as those of the Department of Defense (DoD). Contractors are required to provide pricing for a base year along with four one-year option years, ensuring compliance with federal drug regulations and the Drug Supply Chain Security Act (DSCSA). This procurement is critical for maintaining a reliable supply of pharmaceutical products that meet stringent manufacturing standards and public health requirements. Interested parties must submit their offers by March 4, 2025, at 2:30 PM Central Time, and can contact Contract Specialist Ray Roldan at Raymond.Roldan@va.gov for further information.
    6505--Mycophenolate Mofetil RFP
    Buyer not available
    The Department of Veterans Affairs is seeking proposals for the procurement of Mycophenolate Mofetil capsules and tablets under Solicitation Number 36E79725R0010, aimed at establishing national pricing for these pharmaceutical products. The contract is intended to support various government health care facilities, including those under the Department of Defense and Indian Health Service, ensuring compliance with FDA standards and the Drug Supply Chain Security Act. Offerors are required to submit pricing for both the base year and four option years, with a deadline for submissions extended to March 4, 2025, at 2:30 PM CST, and must acknowledge receipt of this amendment to avoid rejection of their offers. Interested parties can contact Contract Specialist Amber Zavala at amber.zavala@va.gov for further information.
    6509--Solifenacin Tabletes (VA-25-00037090)
    Buyer not available
    The Department of Veterans Affairs (VA) is preparing to issue a Request for Proposal (RFP) for the procurement of Solifenacin Tablets, designated as RFP 36E79725R0020. This procurement aims to establish a reliable supply of Solifenacin for the VA, Department of Defense (DoD), and other federal health agencies, with the contract expected to last one year and include four optional renewal periods. Solifenacin is a critical medication used in the treatment of overactive bladder, highlighting the VA's commitment to ensuring access to essential pharmaceuticals for veterans and associated healthcare providers. Interested vendors should monitor SAM.gov for the RFP release, anticipated around March 14, 2025, with proposals due by March 28, 2025; for further inquiries, they may contact Contract Specialist Kenneth Lay at Kenneth.Lay@va.gov or by phone at 708-786-4879.
    6505--770-25-1-801-0131 -National CMOP DORZOLAMIDE/TIMOLOL -(VA-25-00027395)
    Buyer not available
    The Department of Veterans Affairs is soliciting bids for the procurement of Dorzolamide 22.3/Timolol 6.8mg/ml ophthalmic solution as part of its National Consolidated Mail Outpatient Pharmacy (CMOP) program. This solicitation requires vendors to submit a signed cover page, pricing schedule, and documentation such as a valid state distributor license and a Trade Agreements Act certificate, ensuring compliance with regulatory standards for pharmaceutical products. The procurement is critical for providing quality healthcare services to veterans, emphasizing the importance of product safety, therapeutic equivalence, and adherence to delivery schedules. Interested vendors must submit their quotes by March 5, 2025, at 3:00 PM Central Time, and can contact Contract Specialist Kelley Cunningham at kelley.cunningham@va.gov for further inquiries.
    6505--Hydroxychloroquine SO4 Tablets
    Buyer not available
    The Department of Veterans Affairs (VA) is issuing a Request for Proposal (RFP) for the procurement of Hydroxychloroquine SO4 Tablets, aimed at ensuring a continuous supply for various federal entities, including the Department of Defense and the Bureau of Prisons. The contract will cover an estimated annual requirement of 163,395 bottles of 100-count and 25,853 bottles of 500-count Hydroxychloroquine tablets, with a contract period of one year and four optional one-year extensions. This procurement is critical for maintaining essential medications within veteran and federal healthcare programs. Interested parties should monitor SAM.gov for updates and direct inquiries to the contracting officer, Chris Carthron, at Christopher.Carthron@va.gov or (708) 786-4980, with submissions due by March 26, 2025.
    6525--Nuclear Medicine NEURACEQ F-18 FLORBETABEN PET DEP
    Buyer not available
    The Department of Veterans Affairs is seeking small business vendors to provide F-18 Florbetaben PET doses for the Lexington VA Medical Center, as outlined in the combined synopsis and solicitation (RFQ 36C24925Q0157). The procurement involves a five-year contract for the delivery of specified quantities of radiopharmaceuticals, with orders required to be placed 24 hours prior to patient studies and delivered 15-30 minutes before calibration time. This initiative is crucial for ensuring timely access to essential medical imaging supplies, thereby enhancing the quality of healthcare services provided to veterans. Interested vendors must submit their quotes by March 6, 2025, and can direct inquiries to Contract Specialist Ayslin Kennett at Ayslin.Kennett@va.gov.
    6505--Lab supplies - Radiopharm - Amyvid
    Buyer not available
    The Department of Veterans Affairs is soliciting proposals for a five-year indefinite delivery indefinite quantity (IDIQ) contract to supply Amyvid injectables for Positron Emission Tomography (PET) imaging at the Corporal Michael J. Crescenz VA Medical Center in Philadelphia, Pennsylvania. The contract will require an estimated thirty-six doses of Amyvid per year, which are critical for diagnosing Alzheimer's disease in veterans. Proposals are due by 3:00 PM EST on March 6, 2025, with questions accepted until March 4, 2025, and the total contract value is capped at $1,000,000. Interested vendors must comply with federal regulations and safety guidelines, and they can contact Contracting Officer Victoria Droz at Victoria.Droz@va.gov or 814-515-4454 for further information.